title: Comparison of Abeta(b-/-), H2-DM(-), and CIITA(-/-) in second-set skin allograft rejection.
abstract: BACKGROUND
  Responses against donor MHC antigens are the major contributor to allograft rejection. Currently, it is unclear whether both direct and indirect recognition pathways are necessary and/or sufficient for allograft rejection. Previously, we found donor MHC class II and H2-DM to have dramatic effects on cardiac allograft survival.
  
  
  METHODS
  Here, we used H2-DM(-) mice, which express CLIP-MHC class II complexes, and CIITA(-/-) mice, which lack all class II proteins, to examine the role of direct and indirect recognition on skin allograft rejection. Recipients were primed with donor cultured keratinocytes and later tested for accelerated memory response by challenge with full-thickness tail skin grafts.
  
  
  RESULTS
  As previously reported, Abeta(b-/-) grafts survived longer than wild-type grafts, while H2-DM(-) grafts were rejected as rapidly as wild-type grafts. Skin grafts deficient for both beta2m and H2-DM survived longer than grafts lacking only H2-DM, but not as long as Abeta(b-/-) grafts. Additionally, CIITA(-/-) grafts survived as long as Abeta(b-/-) grafts.
  
  
  CONCLUSIONS
  The delayed rejection of Abeta(b-/-) compared to H2-DM(-) suggests that indirect recognition of surface-expressed donor MHC class II is sufficient to mediate rapid skin allograft rejection. The equivalent survival of CIITA(-/-) and Abeta(b-/-) grafts suggests that indirect presentation of donor class II molecules (Aalpha or Ebeta) present in Abeta(b-/-) but not CIITA(-/-) mice does not contribute to graft rejection. These results reveal a modest role for surface-expressed donor class II in primed keratinocyte rejection, but also reveal a dramatic contrast to the cardiac allograft system and indicate tissue/organ-specific mechanisms of rejection.
authors.affiliation: Lineberger Comprehensive Cancer Center, Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA.
authors.forename: Nathan J
authors.initials: NJ
authors.lastname: Felix
authors.forename: Suzan
authors.initials: S
authors.lastname: de Serres
authors.forename: Anthony A
authors.initials: AA
authors.lastname: Meyer
authors.forename: Jenny P-Y
authors.initials: JP
authors.lastname: Ting
mesh_terms: D000818:Animals; D000944:Antigens, Differentiation, B-Lymphocyte / Q000235:genetics / Q000276:immunology; D002478:Cells, Cultured; D062109:Dermatologic Surgical Procedures; D005260:Female; D015870:Gene Expression / Q000276:immunology; D006084:Graft Rejection / Q000235:genetics / Q000276:immunology*; D006183:H-2 Antigens / Q000235:genetics* / Q000276:immunology; D000949:Histocompatibility Antigens Class II / Q000235:genetics* / Q000276:immunology; D007156:Immunologic Memory; D015603:Keratinocytes / Q000166:cytology / Q000637:transplantation*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D018345:Mice, Knockout; D009687:Nuclear Proteins; D012867:Skin / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D015534:Trans-Activators / Q000235:genetics* / Q000276:immunology; D014184:Transplantation, Homologous
chemical_list: D000944:Antigens, Differentiation, B-Lymphocyte; D006183:H-2 Antigens; D000949:Histocompatibility Antigens Class II; C083728:MHC class II transactivator protein; D009687:Nuclear Proteins; D015534:Trans-Activators; C045084:invariant chain